Figure 8.

YP suppresses LPS-induced inflammatory expression in HSG cells. HSG cells were pretreated with LPS (10 µg/mL) or not for 2 h and subsequently incubated with varying concentrations of YP for 24 h. Immunofluorescence was used to evaluate the expression of TNF-α, IL-1β, and IL-6. The cells were subjected to immunostaining using CY3-labeled antibodies specific to TNF-α, IL-1β, and IL-6. Simultaneously, the cell nuclei were stained blue with DAPI. (A) The levels of TNF-α were reduced after YP treatment compared to the model group, and moderate doses had a significant inhibitory effect on the release of inflammatory factors (B). The levels of IL-1β were decreased after YP treatment in comparison to the model group. Moderate doses of YP notably suppressed the release of inflammatory factors, as observed in 3 representative independent experiments. (C) The levels of IL-6 were diminished after YP treatment compared to the model group, and moderate doses significantly inhibited the release of inflammatory factors. ****, P < .0001; ***, P < .0005; **, P < .005; *, P < .05; ns, no statistically significant difference (P ≥ .05). HSG = Human salivary gland, IL-1β = interleukin 1 beta, IL-6 = interleukin 6, LPS = lipopolysaccharide, TNF-α = tumor necrosis factor, YP = Yiqiyangyinquyu prescription.